Fontan-associated protein losing enteropathy is a challenge to treat and is a major contributor to morbidity and mortality in patients with palliated single ventricle. Numerous strategies for management have been proposed, with confusion as to how best to stratify and implement care among the many treatments available. Medical management can be helpful in some, while novel lymphatic interventions hold potential for remission with good results. We review our institutional approach to protein losing enteropathy after Fontan operation and provide a suggested algorithm and pathway for effective care.
RychikJAtzAMCelermajerDS, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019:CIR0000000000000696.
2.
RychikJ. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis. 2007;2(5):288–300.
3.
JohnASJohnsonJAKhanMDriscollDJWarnesCACettaF. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. J Am Coll Cardiol. 2014;64(1):54–62.
4.
OkanoSSugimotoMTakaseMIsekiKKajihamaAAzumaH. Effectiveness of high-dose spironolactone therapy in a patient with recurrent protein-losing enteropathy after the Fontan procedure. Intern Med. 2016;55(12):1611–1614.
5.
MeadowsJGauvreauKJenkinsK. Lymphatic obstruction and protein-losing enteropathy in patients with congenital heart disease. Congenit Heart Dis. 2008;3(4):269–276.
6.
DoriYKellerMSRychikJItkinM. Successful treatment of plastic bronchitis by selective lymphatic embolization in a Fontan patient. Pediatrics. 2014;134(2):e590–e595.
7.
ItkinMPiccoliDANadolskiG, et al.Protein-losing enteropathy in patients with congenital heart disease. J Am Coll Cardiol. 2017;69(24):2929–2937.
8.
BikoDMDeWittAGPintoEM, et al.MRI evaluation of lymphatic abnormalities in the neck and thorax after Fontan surgery: relationship with outcome. Radiology. 2019;291(3):774–780.
9.
DoriYKellerMSFogelMA, et al.MRI of lymphatic abnormalities after functional single-ventricle palliation surgery. AJR Am J Roentgenol. 2014;203(2):426–431.
10.
KewcharoenJMekraksakitPLimpruttidhamN, et al.Budesonide for protein losing enteropathy in patients with Fontan circulation: A systematic review and meta-analysis. World J Pediatr Congenit Heart Surg. 2020;11(1):85–91.
11.
ThackerDPatelADoddsKGoldbergDJSemeaoERychikJ. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg. 2010;89(3):837–842.
12.
GoldbergDJSurreyLFGlatzAC, et al.Hepatic fibrosis is universal following Fontan operation, and severity is associated with time from surgery: a liver biopsy and hemodynamic study. J Am Heart Assoc. 2017;6(5).
13.
TeliniusNDrewsenNPilegaardH, et al.Human thoracic duct in vitro: diameter-tension properties, spontaneous and evoked contractile activity. Am J Physiol Heart Circ Physiol. 2010;299(3):H811–H818.
14.
TeliniusNKimSPilegaardH, et al.The contribution of K(+) channels to human thoracic duct contractility. Am J Physiol Heart Circ Physiol. 2014;307(1):H33–H43.
15.
MohanakumarSTeliniusNKellyB, et al.Morphology and function of the lymphatic vasculature in patients with a Fontan circulation. Circ Cardiovasc Imaging. 2019;12(4):e008074.
16.
BikoDMSmithCLOteroHJ, et al.Intrahepatic dynamic contrast MR lymphangiography: initial experience with a new technique for the assessment of liver lymphatics. Eur Radiol. 2019;29(10):5190–5196.
17.
HraskaV. Decompression of thoracic duct: new approach for the treatment of failing Fontan. Ann Thorac Surg. 2013;96(2):709–711.
18.
SmithCLHoffmanTMDoriYRomeJJ. Decompression of the thoracic duct: a novel transcatheter approach. Catheter Cardiovasc Interv. 2019.
19.
MaleuxGStormeECoolsB, et al.Percutaneous embolization of lymphatic fistulae as treatment for protein-losing enteropathy and plastic bronchitis in patients with failing Fontan circulation. Catheter Cardiovasc Interv. 2019.
